CancerDrs

Cervical Cancer clinical trials in Michigan

47 actively recruiting cervical cancer trials at 52 sites across Michigan.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting NIH

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in Michigan:
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
  • Trinity Health IHA Medical Group Hematology Oncology - Canton — Canton, Michigan
  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital — Chelsea, Michigan
  • Cancer Hematology Centers - Flint — Flint, Michigan
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Academic/Other

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…

Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in Michigan:
  • University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
  • Wayne State University/Karmanos Cancer Institute — Detroit, Michigan
  • Henry Ford Hospital — Detroit, Michigan
  • Weisberg Cancer Treatment Center — Farmington Hills, Michigan
  • Henry Ford Medical Center-Columbus — Novi, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…

Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Michigan:
  • Research Site — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05451004
Sites in Michigan:
  • University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
  • University of Michigan - Brighton Center for Specialty Care — Brighton, Michigan
  • Henry Ford Hospital — Detroit, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following tre…

Sponsor: Daiichi Sankyo
NCT ID: NCT06644781
Sites in Michigan:
  • Henry Ford Health System — Detroit, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Michigan:
  • MyMichigan Medical Center Gratiot — Alma, Michigan
  • MyMichigan Medical Center Alpena — Alpena, Michigan
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
  • University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
  • Bronson Battle Creek — Battle Creek, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in Michigan:
  • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Michigan:
  • Karmanos Cancer Institute — Detroit, Michigan
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combinatio…

Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT04198766
Sites in Michigan:
  • Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
  • Henry Ford Cancer Institute — Detroit, Michigan
  • START Midwest — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Michigan:
  • Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in HER2-expr…

Sponsor: AstraZeneca
NCT ID: NCT04379596
Sites in Michigan:
  • Research Site — Ann Arbor, Michigan
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of partici…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06469944
Sites in Michigan:
  • The Cancer and Hematology Centers ( Site 6912) — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

Esophageal cancer, which has a low 5-year overall survival rate (\<20%) is increasing in incidence. Previous studies have shown that Hedgehog, AKT, and angiogenic signaling pathways are activated in a significant number of esophageal cance…

Sponsor: VA Office of Research and Development
NCT ID: NCT05563766
Sites in Michigan:
  • VA Ann Arbor Healthcare System, Ann Arbor, MI — Ann Arbor, Michigan
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conduct…

Sponsor: Tanabe Pharma America, Inc.
NCT ID: NCT06943521
Sites in Michigan:
  • START Midwest — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of DM005 in Patients With Advanced Solid Tumors

The goal of this clinical trial is to find out about the safety, efficacy, and tolerability of DM005 for patients with the advanced solid tumors. DM005 is an experimental drug which is not approved by health authorities for the treatment o…

Sponsor: Doma Biopharmaceutical（Suzhou）Co., Ltd.
NCT ID: NCT06515990
Sites in Michigan:
  • Henry Ford Cancer Institute — Detroit, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

This study will be a non-randomized pilot trial using Cyclophosphamide and Sirolimus for the treatment of metastatic differentiated thyroid cancer. Patients will be treated with Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100…

Sponsor: University of Michigan Rogel Cancer Center
NCT ID: NCT03099356
Sites in Michigan:
  • University of Michigan Cancer Center — Ann Arbor, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial

This phase II trial studies how well personalized neck radiation therapy directed by sentinel lymph node biopsy (SLNB) works in treating patients with oral cavity squamous cell carcinoma (OCSCC). SLNB can be performed as part of standard c…

Sponsor: University of Michigan Rogel Cancer Center
NCT ID: NCT07121595
Sites in Michigan:
  • University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)

Single center, non-randomized Phase II study enrolling Stage I-II p16+ oropharyngeal cancer patients to one of two de-escalation treatment paradigms: (1) receive surgery followed by observation or risk-adjusted adjuvant radiation (+/-chemo…

Sponsor: University of Michigan Rogel Cancer Center
NCT ID: NCT05894083
Sites in Michigan:
  • University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two par…

Sponsor: Pfizer
NCT ID: NCT05538130
Sites in Michigan:
  • Brigitte Harris Cancer Pavilion — Detroit, Michigan
  • Henry Ford Hospital — Detroit, Michigan
View on ClinicalTrials.gov →

Showing 25 of 47 trials with sites in Michigan. See all cervical cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-17